Literature DB >> 33887634

Femoral artery-nourished anteromedial thigh flap: A new perspective in oral and maxillofacial defect reconstruction.

Zhaojian Gong1, Shanshan Zhang2, Panchun Li3, Jiang Liu3, Yuming Xu3.   

Abstract

OBJECTIVES: The aim of this study was to evaluate the feasibility and efficacy of the femoral artery (FA)-nourished anteromedial thigh (AMT) flap for reconstructing oral and maxillofacial defects. PATIENTS AND METHODS: The authors analyzed a retrospective case series of 13 patients who underwent the reconstruction of oral and maxillofacial defects with the FA-nourished AMT flap. The flap design and the methods for defect reconstruction are described, and the reconstructive efficacy is reported.
RESULTS: Of the 13 patients, 12 were men, and 1 was woman, with an average age of 52.2 years. Of these FA-supplied AMT flaps, 7 were singly used, 5 were combined with the anterolateral thigh (ALT) flap or its chimeric flaps, and 1 was separately used with the ALT flap. Postoperatively, all flaps survived completely, without vascular compromise or major wound complications.
CONCLUSIONS: The FA-nourished AMT flap can also be used to reconstruct some common oral and maxillofacial defects, especially as a new alternative to the ALT flap. In addition, this flap can be combined with the ALT flap or its chimeric flaps or separately used with the ALT flap for the reconstruction of complex defects.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anterolateral thigh flap; Anteromedial thigh flap; Femoral artery; Oral and maxillofacial defect; Reconstruction; Tumor

Mesh:

Year:  2021        PMID: 33887634     DOI: 10.1016/j.oraloncology.2021.105295

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  1 in total

1.  Reconstruction of Complex Lateral Skull Base Defects After Oral Cancer Resection With Individualized Anterolateral Thigh Flap.

Authors:  Zhaojian Gong; Shanshan Zhang; Chang Chen; Yuan Zhi; Moxin Zi
Journal:  Front Oncol       Date:  2021-09-22       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.